Testing for RET Alterations Gains Traction Across Tumor Types

Ariela Katz
Published: Thursday, Aug 30, 2018
Lynette M. Sholl, MD
Lynette M. Sholl, MD
Testing for RET aberrations is starting to gain importance in clinical practice along with the awareness that RET fusions and mutations are drivers in multiple tumor types. In recent years, tyrosine kinase inhibitors that specifically target RET have entered the pipeline. Although none have yet received FDA approval, the promise of these agents has spurred interest in diagnostic assays that can accurately and efficiently detect RET abnormalities.

, in that something essentially leads to an abnormal event—for instance, when a fusion occurs—and that allows the tumor to propagate irrespective of external signals,” said Lynette M. Sholl, MD, an associate pathologist at Brigham and Women’s Hospital and associate professor at Harvard Medical School in Boston, Massachusetts.

Figure 1. RET Mutations are Common in Medullary Thyroid Cancer1

RET Mutations are Common in Medullary Thyroid Cancer

Figure 2. RET Fusions Occur in a Small Proportion of Tumors1

RET Fusions Occur in a Small Proportion of Tumors
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 22nd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and MyelomaMay 30, 20192.0
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Publication Bottom Border
Border Publication
x